Ohsu Knight Cancer Institute
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Employees
- -
- Market Cap
- -
Olaparib in Combination With Either Durvalumab, Selumetinib, or Capivasertib or Ceralasertib Alone in Treating Patients With Metastatic Triple Negative Breast Cancer
Phase 2
Active, not recruiting
- Conditions
- Metastatic Triple-Negative Breast CarcinomaAnatomic Stage IV Breast Cancer AJCC v8
- Interventions
- Procedure: BiopsyOther: Quality-of-Life Assessment
- First Posted Date
- 2019-01-11
- Last Posted Date
- 2025-03-27
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 27
- Registration Number
- NCT03801369
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
GET FIT Prostate: A Randomized Controlled Exercise Trial
Not Applicable
Completed
- Conditions
- Prostate Carcinoma
- Interventions
- Other: StretchingOther: Resistance TrainingOther: Tai Chi
- First Posted Date
- 2018-11-14
- Last Posted Date
- 2024-10-22
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 335
- Registration Number
- NCT03741335
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
MoleMapper, Visiomed, and Confocal Microscopy in Screening Participants for Melanoma
Not Applicable
Recruiting
- Conditions
- Cutaneous MelanomaSkin CarcinomaMelanocytic Nevus
- Interventions
- Other: Confocal MicroscopyOther: DermoscopyProcedure: Imaging ProcedureProcedure: Punch BiopsyProcedure: Shave Biopsy
- First Posted Date
- 2018-10-09
- Last Posted Date
- 2025-01-09
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 100
- Registration Number
- NCT03699995
- Locations
- 🇺🇸
Sancy Leachman, Portland, Oregon, United States
Video Distraction to Decrease Use of Sedation in Pediatric Participants During Radiation Therapy
Phase 1
Completed
- Conditions
- Malignant Neoplasm
- Interventions
- Other: Quality-of-Life AssessmentOther: Questionnaire AdministrationRadiation: Radiation TherapyOther: Video
- First Posted Date
- 2018-09-19
- Last Posted Date
- 2020-05-04
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 6
- Registration Number
- NCT03677531
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Feasibility of FMISO in Brain Tumors
Phase 2
Recruiting
- Conditions
- Malignant Brain Neoplasm
- Interventions
- Drug: ¹⁸F-FluoromisonidazoleProcedure: Computed TomographyProcedure: Magnetic Resonance ImagingProcedure: Positron Emission TomographyProcedure: Oxygen Therapy
- First Posted Date
- 2018-08-28
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 50
- Registration Number
- NCT03649880
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Exercise Program Among Lung Cancer Dyads
Not Applicable
Completed
- Conditions
- Quality of LifePainPhysical ActivityLung Cancer SymptomsLung CancerDepression
- Interventions
- Behavioral: Exercise InterventionOther: Survey AdministrationOther: Quality-of-Life Assessment
- First Posted Date
- 2018-08-28
- Last Posted Date
- 2020-12-09
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 46
- Registration Number
- NCT03649737
- Locations
- 🇺🇸
Oregon Health and Science University, Portland, Oregon, United States
🇺🇸VA Portland Health Care System, Portland, Oregon, United States
EXERCISING TOGETHER for Couples Coping With Cancer
Not Applicable
Completed
- Conditions
- Stage I Prostate Cancer AJCC v8Anatomic Stage I Breast Cancer AJCC v8Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8Malignant Solid NeoplasmColorectal CarcinomaBreast CarcinomaStage I Colorectal Cancer AJCC v8Stage II Colorectal Cancer AJCC v8Stage III Prostate Cancer AJCC v8
- Interventions
- Behavioral: Exercise InterventionOther: Questionnaire AdministrationOther: Informational Intervention
- First Posted Date
- 2018-08-14
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 534
- Registration Number
- NCT03630354
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Bone Marrow Transplantation Using CD34-Selected Stem Cells From Related or Unrelated Donors in Treating Participants With Cancer or Other Disorders
- Conditions
- Hematopoietic Cell Transplantation RecipientMalignant NeoplasmBenign NeoplasmBone Marrow Transplantation Recipient
- First Posted Date
- 2018-08-13
- Last Posted Date
- 2024-08-16
- Lead Sponsor
- OHSU Knight Cancer Institute
- Registration Number
- NCT03626285
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Fluorothymidine F-18 PET in Diagnosing Patients With Intermediate or High Grade Soft Tissue Sarcoma
Early Phase 1
Withdrawn
- Conditions
- Stage III Adult Soft Tissue SarcomaStage II Adult Soft Tissue SarcomaStage IIA Adult Soft Tissue SarcomaStage IIB Adult Soft Tissue SarcomaStage IIC Adult Soft Tissue SarcomaStage IV Adult Soft Tissue Sarcoma
- Interventions
- Other: Laboratory Biomarker AnalysisProcedure: Positron Emission Tomography
- First Posted Date
- 2018-08-03
- Last Posted Date
- 2020-06-09
- Lead Sponsor
- OHSU Knight Cancer Institute
- Registration Number
- NCT03613259
JNJ-40346527 in Treating Participants With Relapsed or Refractory Acute Myeloid Leukemia
Phase 2
Terminated
- Conditions
- Recurrent Acute Myeloid LeukemiaRefractory Acute Myeloid Leukemia
- Interventions
- Other: Pharmacokinetic Study
- First Posted Date
- 2018-06-15
- Last Posted Date
- 2021-12-02
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 3
- Registration Number
- NCT03557970
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
© Copyright 2025. All Rights Reserved by MedPath